Ezharmia Tablet Post-marketing Surveillance
Not Applicable
Recruiting
- Conditions
- Relapsed or refractory Adult T-cell leukemia/lymphoma (ATL)
- Registration Number
- JPRN-jRCT2031220503
- Lead Sponsor
- Matsuoka Yomei
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
All patients who start receiving Ezharmia Tablet during the registration period.
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cumulative incidence of AEs (safety specifications of the survey and other AEs)
- Secondary Outcome Measures
Name Time Method